IL-28A/IFN-lambda 2 Inhibition of EMCV-induced Cytopathy and Neutralization by Human IL-28A/IFN-lambda 2 Antibody. Recombinant Human IL-28A/ IFN-lambda 2 (Catalog # 1587-IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Inhibition of EMCV activity elicited by Recombinant Human IL-28A/IFN-lambda 2 (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL-28A/IFN-lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587). The ND₅₀ is typically 0.3-1.5 µg/mL.

IL-28A/IFN-lambda 2 in Human PBMCs. IL-28A/IFN-lambda 2 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) using Goat Anti-Human IL-28A/IFN-lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) at 15 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Human IL-28A/IFN-lambda 2 ELISA Standard Curve. Recombinant Human IL-28A/IFN-lambda 2 protein was serially diluted 2-fold and captured by Mouse Anti-Human IL-28A/IFN-lambda 2 Monoclonal Antibody (Catalog # MAB15872) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human IL-28A/IFN-lambda 2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1587) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998) followed by Substrate Solution (Catalog # DY999) and stopping the enzymatic reaction with Stop Solution (Catalog # DY994).